Almstead Neil Gregory sold $2.3M of PTCT
Almstead Neil Gregory (CHIEF TECHNICAL OPS OFFICER) sold 26,283 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $85.78 ($85.01–$87.00, $2.25M total) across 7 trades over 2026-06-24 to 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market sale totaling ~$2.25M across 7 trades at ~$85.01–$87.00, executed under a pre-arranged 10b5-1 plan.
Market read
This is a routine insider-selling disclosure; it may slightly affect sentiment but lacks accompanying fundamental catalysts in the text.
What to watch
The article provides only the sale mechanics (size, price range, 10b5-1 flag) and not any concurrent operational/financial updates, so traders should avoid over-interpreting intent.
Background
SEC Form 4 insider transaction for PTC Therapeutics, Inc. (PTCT) by Almstead Neil Gregory (Chief Technical Operations Officer).
Ticker impact
PTCT insider Form 4 shows CFO Almstead Neil Gregory sold 26,283 shares for ~$2.25M across 7 trades under a 10b5-1 plan.
Low near-term impact; any effect is likely muted and short-lived unless paired with other new company-specific catalysts.
The filing is a primary-source Form 4, but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive weight for near-term price direction.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
No clear regional spillover implied by the text.
Limited global relevance; disclosure pertains to a US-listed issuer.
Counterpoint
Even with a 10b5-1 plan, clustered sales by a key tech operations officer can still coincide with internal expectations of near-term risk, though the filing itself doesn’t provide that rationale.
Key entities
- issuerPTC Therapeutics, Inc.
Company whose insider transaction is disclosed via SEC Form 4.
- insiderAlmstead Neil Gregory
Chief Technical Operations Officer who sold shares under a 10b5-1 plan.
